Covered recipient · General Payments record
TIMOTHY J PANELLA
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$2,726.53
138 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,526.59 | 136 |
| Education | $199.94 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TIMOTHY J PANELLA
NPI 1801908223 · CMS profile ID 172406
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
KNOXVILLE, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1801908223?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TIMOTHY J PANELLA, NPI 1801908223, CMS profile ID 172406. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801908223?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). TIMOTHY J PANELLA, NPI 1801908223, CMS profile ID 172406. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801908223?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- TIMOTHY J PANELLA, NPI 1801908223, CMS profile ID 172406, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1801908223?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
138 matching records · $2,726.53 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 138.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $20.38 | 08/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223860622 | CMS |
| Merck Sharp & Dohme LLC | $15.53 | 08/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238301665 | CMS |
| Merck Sharp & Dohme LLC | $24.42 | 08/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238109040 | CMS |
| Regeneron Healthcare Solutions, Inc. | $23.38 | 08/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213006268 | CMS |
| ABBVIE INC. | $24.18 | 08/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203449405 | CMS |
| Regeneron Pharmaceuticals, Inc. | $38.13 | 08/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213241759 | CMS |
| Genentech USA, Inc. | $17.27 | 07/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211601448 | CMS |
| Immunocore Limited | $26.73 | 07/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235825494 | CMS |
| Merck Sharp & Dohme LLC | $14.93 | 07/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238072272 | CMS |
| Merck Sharp & Dohme LLC | $23.75 | 07/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238169094 | CMS |
| Novartis Pharmaceuticals Corporation | $23.39 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200690702 | CMS |
| Gilead Sciences, Inc. | $16.37 | 07/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234562899 | CMS |
| Syndax Pharmaceuticals, Inc. | $16.36 | 07/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238994018 | CMS |
| AstraZeneca Pharmaceuticals LP | $32.43 | 07/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207250538 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5.24 | 07/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184892638 | CMS |
| ABBVIE INC. | $19.96 | 07/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203449401 | CMS |
| E.R. Squibb & Sons, L.L.C. | $11.39 | 07/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184892640 | CMS |
| Regeneron Healthcare Solutions, Inc. | $16.14 | 07/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213006266 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.47 | 06/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184892630 | CMS |
| Novartis Pharmaceuticals Corporation | $19.66 | 06/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200690694 | CMS |
| E.R. Squibb & Sons, L.L.C. | $10.11 | 06/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184892642 | CMS |
| E.R. Squibb & Sons, L.L.C. | $8.58 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184892628 | CMS |
| Genentech USA, Inc. | $20.82 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211601452 | CMS |
| Deciphera Pharmaceuticals Inc. | $17.89 | 06/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235960663 | CMS |
| Merck Sharp & Dohme LLC | $25.30 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238177929 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.87 | 06/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213006264 | CMS |
| Blueprint Medicines Corporation | $23.42 | 06/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235813849 | CMS |
| Merck Sharp & Dohme LLC | $16.56 | 06/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238022182 | CMS |
| Novartis Pharmaceuticals Corporation | $16.16 | 06/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200690688 | CMS |
| E.R. Squibb & Sons, L.L.C. | $7.22 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184892644 | CMS |
| Regeneron Healthcare Solutions, Inc. | $33.64 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213006262 | CMS |
| Incyte Corporation | $19.86 | 06/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226123075 | CMS |
| ADC THERAPEUTICS AMERICA, INC. | $17.54 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246127341 | CMS |
| Merck Sharp & Dohme LLC | $17.27 | 05/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238264996 | CMS |
| Gilead Sciences, Inc. | $6.62 | 05/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234596501 | CMS |
| PFIZER INC. | $15.89 | 05/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231327819 | CMS |
| Exelixis Inc. | $24.46 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218806659 | CMS |
| Gilead Sciences, Inc. | $18.66 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234542663 | CMS |
| E.R. Squibb & Sons, L.L.C. | $9.84 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184892604 | CMS |
| Regeneron Pharmaceuticals, Inc. | $32.47 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213241757 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $14.01 | 05/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251745426 | CMS |
| Janssen Biotech, Inc. | $17.66 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174865070 | CMS |
| Agios Pharmaceuticals, Inc. | $19.53 | 04/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253246128 | CMS |
| Gilead Sciences, Inc. | $25.29 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234471912 | CMS |
| Novartis Pharmaceuticals Corporation | $11.53 | 04/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200690682 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.51 | 04/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184892612 | CMS |
| Merck Sharp & Dohme LLC | $14.10 | 04/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238259229 | CMS |
| Celgene Corporation | $20.25 | 04/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184892594 | CMS |
| Daiichi Sankyo Inc. | $19.33 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197060207 | CMS |
| E.R. Squibb & Sons, L.L.C. | $10.85 | 04/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184892590 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $693.33 | 2 |
| PY2025 | Principal investigator | $845,696.75 | 344 |
| PY2024 | Recipient | $5,166.06 | 2 |
| PY2024 | Principal investigator | $441,512.56 | 140 |
| PY2023 | Recipient | $9,588.72 | 30 |
| PY2023 | Principal investigator | $274,060.55 | 82 |
| PY2022 | Recipient | $6,062.10 | 15 |
| PY2022 | Principal investigator | $203,797.88 | 43 |
| PY2021 | Recipient | $4,470.00 | 3 |
| PY2021 | Principal investigator | $689,400.90 | 45 |
| PY2020 | Principal investigator | $445,623.55 | 29 |
| PY2019 | Principal investigator | $587,903.01 | 21 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
346 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $291.82 | 12/31/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - KEYNOTE-355 | No dispute reported | 06/30/2026 | 1232926323 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $11,443.75 | 12/31/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 | No dispute reported | 06/30/2026 | 1232926413 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,855.20 | 12/19/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184140347 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,573.78 | 12/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140333 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,964.20 | 12/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140335 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $437.43 | 12/04/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140327 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,151.67 | 12/04/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140329 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 11/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140315 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $550.00 | 11/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140317 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 11/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140319 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,781.63 | 11/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140321 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 11/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140323 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 11/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140325 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 11/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140311 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 11/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140313 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $331.66 | 11/20/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140303 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,325.14 | 11/20/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140307 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 11/19/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140295 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 11/19/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140297 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 11/19/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140299 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 11/19/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140301 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,678.56 | 11/14/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140293 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 11/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140281 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 11/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140283 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 11/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140285 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 11/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140287 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 11/05/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140267 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 11/05/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140269 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 11/05/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140271 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 11/05/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,776.34 | 11/05/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140275 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.13 | 11/05/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140277 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 10/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140253 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 10/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140255 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,781.63 | 10/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140257 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 10/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140259 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 10/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140261 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $550.00 | 10/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140263 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 10/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140265 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,530.00 | 10/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140241 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $350.63 | 10/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140243 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 10/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140245 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 10/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140247 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 10/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140249 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 10/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140251 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $605.00 | 10/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140233 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 10/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140235 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,621.38 | 10/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140237 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $219.93 | 10/23/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140227 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,150.21 | 10/23/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140231 |
| Principal investigator 1 | Immunocore Limited | $1,282.88 | 10/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146333 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 10/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140205 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,781.63 | 10/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140209 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 10/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140211 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $550.00 | 10/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140213 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 10/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140215 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 10/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140217 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 10/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140219 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,573.78 | 10/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140191 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,964.20 | 10/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140193 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $107.82 | 10/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140197 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,001.46 | 10/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140203 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140149 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $625.60 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140152 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $625.60 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140156 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,470.50 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140159 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,470.50 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140163 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,470.50 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140166 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140169 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,708.10 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140173 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,714.05 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140177 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,777.80 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140179 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140181 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140183 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,301.35 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140185 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 09/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140187 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 09/25/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140122 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $350.63 | 09/25/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140126 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 09/25/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140130 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 09/25/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140135 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,530.00 | 09/25/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140141 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 09/25/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140144 |
| Principal investigator 1 | Immunocore Limited | $1,271.88 | 09/24/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146331 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 09/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140097 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 09/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140102 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 09/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140106 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,530.00 | 09/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140110 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 09/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $350.63 | 09/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140117 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,097.17 | 09/18/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140094 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 09/17/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140076 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $20.04 | 09/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140063 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $312.00 | 09/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140067 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,150.21 | 09/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184140072 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 09/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140038 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 09/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140043 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $350.63 | 09/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140047 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,530.00 | 09/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140051 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 09/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140055 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 09/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140059 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 09/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139991 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $350.63 | 09/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139996 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,530.00 | 09/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140001 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 09/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140006 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 09/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140010 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 09/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184140014 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $1,200.00 | 08/26/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | BelieveIT-201 | No dispute reported | 06/30/2026 | 1233996715 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,001.46 | 08/26/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139986 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $208.00 | 08/21/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139955 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11.93 | 08/21/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139959 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,001.46 | 08/21/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139967 |
| Principal investigator 1 | AstraZeneca UK Limited | $14,111.90 | 08/15/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | No dispute reported | 06/30/2026 | 1185552735 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 08/14/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139948 |
| Principal investigator 1 | Immunocore Limited | $605.00 | 08/13/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146317 |
| Principal investigator 1 | Immunocore Limited | $1,175.63 | 08/13/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146319 |
| Principal investigator 1 | Immunocore Limited | $673.75 | 08/13/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146321 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139888 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139892 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,115.25 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139896 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,609.90 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139900 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139904 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,777.80 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $625.60 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139911 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139916 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,714.05 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139920 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,714.05 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139923 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,714.05 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139931 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,470.50 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139935 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139939 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 08/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139944 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,150.21 | 08/07/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139884 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $239.26 | 08/04/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | BelieveIT-201 | No dispute reported | 06/30/2026 | 1233996633 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,150.21 | 07/31/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139875 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7.64 | 07/22/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139855 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $208.00 | 07/22/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139859 |
| Principal investigator 1 | Immunocore Limited | $673.75 | 07/18/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146323 |
| Principal investigator 1 | Immunocore Limited | $605.00 | 07/18/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146325 |
| Principal investigator 1 | Immunocore Limited | $1,271.88 | 07/18/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146327 |
| Principal investigator 1 | Immunocore Limited | $605.00 | 07/18/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146329 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,001.46 | 07/17/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139832 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 07/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139824 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 07/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139828 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $416.00 | 07/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139801 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $32.44 | 07/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139806 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,001.46 | 07/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139815 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,710.40 | 07/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184139819 |
| Principal investigator 1 | Immunocore Limited | $1,100.00 | 07/02/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146307 |
| Principal investigator 1 | Immunocore Limited | $3,616.25 | 07/02/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146309 |
| Principal investigator 1 | Immunocore Limited | $605.00 | 07/02/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146311 |
| Principal investigator 1 | Immunocore Limited | $605.00 | 07/02/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146313 |
| Principal investigator 1 | Immunocore Limited | $1,443.75 | 07/02/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146315 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 06/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139772 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.13 | 06/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139777 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 06/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139779 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,776.13 | 06/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139782 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 06/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139786 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 06/30/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139790 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $350.63 | 06/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139731 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 06/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139734 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 06/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139739 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $605.00 | 06/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139743 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $605.00 | 06/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139747 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,530.00 | 06/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139752 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 06/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139756 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 06/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139759 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,621.38 | 06/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139764 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,621.38 | 06/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139768 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,257.42 | 06/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139728 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 06/23/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139720 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $512.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139623 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $512.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139625 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $512.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139627 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $625.60 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139629 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $625.60 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139631 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $787.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139633 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,022.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139635 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,022.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139637 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,056.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139639 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,097.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139641 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,107.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139643 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,107.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139645 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,173.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139647 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,191.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139649 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,230.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139651 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,297.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139653 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,297.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139655 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,331.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139657 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,382.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139659 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,382.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139661 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,538.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139663 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,578.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139665 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139667 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139669 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139673 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,877.25 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139677 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,877.25 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139681 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139683 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139687 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139690 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,115.25 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139694 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,255.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139698 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,220.00 | 06/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139703 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,150.21 | 06/12/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139621 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,279.40 | 06/05/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139611 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,378.00 | 06/05/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139613 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,573.78 | 06/05/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139615 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $539.20 | 06/01/2025 | Covered Recipient Physician | LIBTAYO CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1184121157 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $625.60 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139519 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,959.30 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,968.20 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139527 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,852.20 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139529 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,115.25 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139531 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $625.60 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139535 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139537 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,959.30 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139539 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139541 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,852.20 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,115.25 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,877.25 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139553 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,777.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139555 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,959.30 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139557 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,777.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139559 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139561 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,777.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139565 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,708.10 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139567 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,115.25 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139569 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139571 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,115.25 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139573 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139575 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,714.05 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139577 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,852.20 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139579 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139581 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,968.20 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139583 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,777.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139585 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,946.95 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139587 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,777.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139589 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,777.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139591 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,968.20 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139593 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,301.35 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139595 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,539.80 | 05/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139597 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,001.46 | 05/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139517 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,781.63 | 05/23/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139491 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 05/23/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139493 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $550.00 | 05/23/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139495 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 05/23/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139497 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 05/23/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139499 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 05/23/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139501 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,621.38 | 05/23/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139503 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $605.00 | 05/23/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 05/22/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184139487 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $250.00 | 05/21/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | TranscendIT-101 | No dispute reported | 06/30/2026 | 1233995657 |
| Principal investigator 1 | Immunocore Limited | $189.00 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146275 |
| Principal investigator 1 | Immunocore Limited | $189.00 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146277 |
| Principal investigator 1 | Immunocore Limited | $9,704.75 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146279 |
| Principal investigator 1 | Immunocore Limited | $199.38 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146281 |
| Principal investigator 1 | Immunocore Limited | $9,704.75 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146283 |
| Principal investigator 1 | Immunocore Limited | $4,452.25 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146285 |
| Principal investigator 1 | Immunocore Limited | $2,145.00 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146287 |
| Principal investigator 1 | Immunocore Limited | $2,557.50 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146289 |
| Principal investigator 1 | Immunocore Limited | $4,083.75 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146291 |
| Principal investigator 1 | Immunocore Limited | $1,072.50 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146293 |
| Principal investigator 1 | Immunocore Limited | $605.00 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146295 |
| Principal investigator 1 | Immunocore Limited | $3,984.75 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146297 |
| Principal investigator 1 | Immunocore Limited | $1,677.50 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146299 |
| Principal investigator 1 | Immunocore Limited | $1,475.38 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146301 |
| Principal investigator 1 | Immunocore Limited | $1,100.00 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146303 |
| Principal investigator 1 | Immunocore Limited | $1,168.75 | 05/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146305 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $23,674.76 | 05/15/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | BelieveIT-201 | No dispute reported | 06/30/2026 | 1233995605 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $500.00 | 05/15/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | BelieveIT-201 | No dispute reported | 06/30/2026 | 1233995619 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 05/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139477 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 05/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139479 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 05/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139481 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 05/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139483 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,257.42 | 05/08/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139475 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,825.00 | 05/02/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184139469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,552.00 | 05/02/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184139471 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 05/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $350.63 | 05/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139459 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 05/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139461 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 05/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139463 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 05/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139465 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,530.00 | 05/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139467 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $2,406.25 | 04/17/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | TranscendIT-101 | No dispute reported | 06/30/2026 | 1233995525 |
| Principal investigator 1 | Immunocore Limited | $189.00 | 04/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146259 |
| Principal investigator 1 | Immunocore Limited | $189.00 | 04/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146261 |
| Principal investigator 1 | Immunocore Limited | $1,942.88 | 04/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146263 |
| Principal investigator 1 | Immunocore Limited | $1,567.50 | 04/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146265 |
| Principal investigator 1 | Immunocore Limited | $1,636.25 | 04/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146267 |
| Principal investigator 1 | Immunocore Limited | $1,911.25 | 04/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146269 |
| Principal investigator 1 | Immunocore Limited | $1,567.50 | 04/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146271 |
| Principal investigator 1 | Immunocore Limited | $2,090.00 | 04/16/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $589.88 | 04/14/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,814.63 | 04/14/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139431 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,746.88 | 04/14/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139433 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.25 | 04/14/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139435 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $2,252.24 | 04/11/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | TranscendIT-101 | No dispute reported | 06/30/2026 | 1233995323 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 04/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139427 |
| Principal investigator 1 | Eli Lilly and Company | $4,035.00 | 04/08/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187875469 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $154.13 | 03/25/2025 | Covered Recipient Physician | LIBTAYO CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1184121155 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $250.00 | 03/19/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | TranscendIT-101 | No dispute reported | 06/30/2026 | 1233995221 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 03/17/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139417 |
| Principal investigator 1 | Eli Lilly and Company | $2,000.20 | 03/10/2025 | Non-covered Recipient Entity UNIVERSITY OF TENNESSEE | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187893392 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $6,943.50 | 03/06/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | TranscendIT-101 | No dispute reported | 06/30/2026 | 1233995155 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $300.00 | 02/20/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | BelieveIT-201 | No dispute reported | 06/30/2026 | 1233994847 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $605.00 | 02/20/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139407 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,621.38 | 02/20/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139409 |
| Principal investigator 1 | Immunocore Limited | $250.00 | 02/03/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146245 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,592.50 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139373 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,224.45 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139375 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,394.45 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139377 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,199.35 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139379 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,421.65 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139381 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,983.05 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139383 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,153.90 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139385 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,421.65 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139387 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,153.90 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139389 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,421.65 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139391 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,224.45 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139393 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,983.05 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139395 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,592.50 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139397 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,153.90 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139399 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,224.45 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139401 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,983.05 | 02/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | No dispute reported | 06/30/2026 | 1184139403 |
| Principal investigator 1 | BioNTech SE | $5,000.00 | 01/29/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | BNT327-02 | No dispute reported | 06/30/2026 | 1249014347 |
| Principal investigator 1 | BioNTech SE | $2,900.00 | 01/29/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | BNT327-02 | No dispute reported | 06/30/2026 | 1249014349 |
| Principal investigator 1 | BioNTech SE | $12,000.00 | 01/29/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | BNT327-02 | No dispute reported | 06/30/2026 | 1249014351 |
| Principal investigator 1 | Immunocore Limited | $9,705.00 | 01/24/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146247 |
| Principal investigator 1 | Immunocore Limited | $189.00 | 01/24/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146249 |
| Principal investigator 1 | Immunocore Limited | $189.00 | 01/24/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146251 |
| Principal investigator 1 | Immunocore Limited | $189.00 | 01/24/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146253 |
| Principal investigator 1 | Immunocore Limited | $189.00 | 01/24/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146255 |
| Principal investigator 1 | Immunocore Limited | $189.00 | 01/24/2025 | Non-covered Recipient Entity University Health System, Inc. | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212146257 |
| Principal investigator 1 | AstraZeneca UK Limited | $19,469.85 | 01/22/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 | No dispute reported | 06/30/2026 | 1185552733 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $25,095.25 | 01/14/2025 | Covered Recipient Teaching Hospital University Of Tennessee Medical Cent | TranscendIT-101 | No dispute reported | 06/30/2026 | 1233993932 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,885.00 | 01/13/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139361 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 01/13/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184139363 |
| Principal investigator 1 | Eli Lilly and Company | $36,473.00 | 01/06/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF TENNESSEE MEDICAL CENT | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187875467 |